Jean Macenat, MD
Internal Medicine · Bronx, NYNPI 1104886860
Payments from drug & device makers
Across 614 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- AstraZeneca$1K
- Amgen$1K
- Merck$703
- Bayer$596
- Boehringer Ingelheim$520
- plus $5K from 30 others
What the payments were for
- Food & beverage$11,965100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 185 | $2,888 |
| AstraZeneca | 66 | $1,315 |
| Amgen(2 entities) | 56 | $1,090 |
| Merck | 36 | $703 |
| Bayer | 25 | $596 |
| Boehringer Ingelheim | 17 | $520 |
| Teva Pharmaceuticals USA, Inc. | 20 | $488 |
| Lilly USA, LLC | 25 | $439 |
| Novo Nordisk | 21 | $419 |
| Amarin Pharma, Inc. | 20 | $392 |
| Sanofi-aventis U.S. LLC | 17 | $371 |
| GSK | 14 | $331 |
| Mannkind Corporation | 13 | $265 |
| Novartis | 13 | $259 |
| Ardelyx, Inc. | 11 | $243 |
| Aimmune Therapeutics, Inc. | 10 | $232 |
| Ironwood Pharmaceuticals, Inc | 10 | $215 |
| Pfizer | 10 | $215 |
| Nestle Healthcare Nutrition Inc. | 7 | $142 |
| Astellas Pharma US Inc | 6 | $126 |
| Gilead | 1 | $119 |
| Johnson & Johnson(2 entities) | 6 | $109 |
| Abbott | 4 | $101 |
| Lundbeck LLC | 3 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $49 |
| Alkermes, Inc. | 2 | $41 |
| Exact Sciences | 2 | $37 |
| Avanir Pharmaceuticals, Inc. | 2 | $37 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $33 |
| Neurelis, Inc. | 1 | $30 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Napo Pharmaceuticals Inc | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Althera Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,982 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 205 | $212,231 |
| TrulicityDulaglutide | 109 | $129,717 |
| LinzessLinaclotide | 137 | $123,107 |
| OzempicSemaglutide | 115 | $119,301 |
| EliquisApixaban | 110 | $106,368 |
| FarxigaDapagliflozin Propanediol | 123 | $88,695 |
| EntrestoSacubitril/Valsartan | 71 | $81,902 |
| Naproxen-Esomeprazole MagNaproxen/Esomeprazole Mag | 56 | $70,096 |
| ZenpepLipase/Protease/Amylase | 18 | $68,518 |
| JanuviaSitagliptin Phosphate | 70 | $63,819 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $36,729 |
| MounjaroTirzepatide | 33 | $34,640 |
| TivicayDolutegravir Sodium | 12 | $27,234 |
| RybelsusSemaglutide | 21 | $25,860 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 18 | $25,430 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto | $520 | $235,430229 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $439 | $164,357142 claims |
| Novo NordiskOzempic, Rybelsus | $419 | $145,160136 claims |
| AbbVieLinzess | $2,888 | $123,107137 claims |
| PfizerEliquis | $215 | $106,368110 claims |
| AstraZenecaFarxiga, Lokelma | $1,315 | $96,104135 claims |
| MerckJanuvia, Janumet, Dulera | $703 | $92,914105 claims |
| NovartisEntresto | $259 | $81,90271 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $331 | $71,328108 claims |
| Aimmune Therapeutics, Inc.Zenpep | $232 | $68,51818 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $371 | $24,51330 claims |
| Johnson & JohnsonXarelto | $109 | $17,01811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Bronx
- Benjamin GartrellBronx$6.3M
- David SteinBronx$2.4M
- Haiying ChengBronx$1.7M
- Jason LeiderBronx$1.4M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.